Testing mirikizumab in healthy volunteers
Treatments studied
This study is testing a new medicine called mirikizumab in healthy people to see how it works in the body. Healthy volunteers help researchers understand the drug's safety before it is studied in patients with a disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be generally healthy, based on a medical check-up and lab tests.
- Your body mass index (BMI) must be between 18.0 and 34.0.
- You cannot have any major allergies to medicines like mirikizumab.
- You cannot have a weakened immune system or an active infection.
- You must not have taken any other biologic drugs in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new investigational medicine in healthy adults to see how safe it is and how the body processes it. It is a first-in-human trial, so it is looking for volunteers who are generally well and have normal immune function.
This trial tests a new medicine, currently known by the code LY4355756, in healthy people to check its safety and how the body handles it. Your participation could help show if this medicine is safe enough to move into larger testing.
This study tests a medication called mirikizumab (an injection) in people over 60 with moderate to severe Crohn's disease or ulcerative colitis. The goal is to see if it effectively reduces inflammation and helps symptoms, while also checking how safe it is for older adults.
This study tests a new medicine called mirikizumab for people with ulcerative colitis or Crohn's disease who have not responded well to other treatments. It aims to see if mirikizumab can help control symptoms and improve quality of life.
This study checks whether continuing mirikizumab (a medicine that calms gut inflammation) helps children with ulcerative colitis or Crohn’s disease after prior study treatment. It aims to see if staying on the medicine is beneficial and safe over time.
This study measures how much of the medication mirikizumab passes into breast milk when mothers take it for their approved medical condition. The goal is to understand if it's safe for breastfeeding infants when mothers are receiving this treatment.
Hear when a new Healthy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.